The NFL Alumni Association Joins Cancer Treatment Centers of America in Fight Against Cancer

The NFL Alumni Association, the Cancer Treatment Centers of America and LabCorp have joined together to fight prostate cancer. One in seven men will be diagnosed with prostate cancer each year, and if you are African American the statistic is one out of five men will get prostate cancer each year.

The drive is to get men to have a PSA screening, which can be an indication that prostate cancer is present. LabCorp is offering the screening for only $25 which can be taken at one of the LabCorp medical labs located nearly everywhere in the country. If detected early enough, steps can be taken to deal with the prostate cancer effectively.

The Cancer Treatment Centers of America is a well=known cancer-fighting facility which aggressively treats cancer and nothing else. Cancer is their specialty and the not only use the traditional treatments such as surgery, chemotherapy, and radiation but other less ordinary methods as well.

CTSA uses treatments such as acupuncture for pain, herbal medication, diet and nutrition, and other, sometimes experimental methods to treat cancer. They call it integrated treatment where the traditional methods of treatment are used along with other innovative approaches.

Personalities Herm Edwards, Bill Cowher, and Dick Vermeil spokesmen for the project, called Prostate Pep Talk. Edwards talks about friends who have been lost to prostate cancer and his father who had surgery for it. All men have to do is get screened on regular basis. Many men just put it off with disastrous results.

Cancer Treatment Centers of America has fully equipped hospitals in Philadelphia, Chicago, Phoenix, Tulsa, and Atlanta. People who have cancer can come for treatment and stay during their regimen along with their families. CTCA believes that cancer is an individualistic disease and that treatment has to be individualized. For this reason each patient receives an individual evaluation and treatment.

To Learn More Click Here

Oncotarget, a Validated Resource for Medical Breakthroughs

Oncotarget is a journal made to highlight the impact made as far as cancer research and oncology is concerned. From the very beginning, Oncotarget has been the only platform where people can a get a diversity of resources centering on topics like immunology, physiology, aging, age related diseases, stem cell, neuroscience, cell diseases, autophagy, chromosome, pathology, and endocrinology.For your piece to get featured on Oncotarget, it has to be as original as possible. All research work must be backed up by empirical evidence that has gotten tested over time.For years, Oncotarget has concentrated on the field of Oncology, with a particular interest getting placed on cancer and aging.

Thanks to the journal, people, and scientists from all across the globe now have the chance to find useful resources on the two topics mentioned above. With information getting updated on a weekly basis, Oncotarget has become a reliable reference point for most medical researchers. Oncotarget has been able to enjoy much success because of its devoted editors who are none other than Andrei V. Gudkov and Mikhail Blagosklonny.In the seven years that Oncotarget has been in existence, it has enjoyed an unlimited number of views making an average journal impact of close to four. Oncotarget has been able to evolve taking advantage of social media platforms to gain some mileage.

Today, you can easily access Oncotarget through LinkedIn , Google+, Twitter, YouTube, and Facebook. With an impact factor averaging five, it is proof enough that Oncotarget is a much sought after journal, mainly because of relevance and authenticity.It is a diary backed up by highly researched information, from trusted sources like Mikhail Blagosklonny, a researcher renowned for his passion for scrutinizing scientific evidence with an open mind. Seven years down the line, Oncotarget holds much ground and is the most preferred journal as far as medical research is concerned. Any information posted on Oncotarget remains easily accessible, meaning that there is no discrimination whatsoever as to who should access data from the journal. With such an encouraging reputation, Oncotarget holds a promising future, particularly for its readers.